Latest Breaking News On - Topline results expected - Page 4 : comparemela.com

HMNC Brain Health and Develco Pharma Announce Last Patient Being Randomized in Oral Prolonged-Release Ketamine (KET01) Trial for Treatment-Resistant Depression

HMNC Brain Health and Develco Pharma Announce Last Patient Being Randomized in Oral Prolonged-Release Ketamine (KET01) Trial for Treatment-Resistant Depression
finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.

South africaSwitzerland generalBaden wübergDevelco pharmaAnne donohoeSophia bashfordHans erikssonKetabon programHolding gmbBrain healthTopline results expectedTreatment resistant depressionChief medical officerDepression rating scaleMajor depressive disorderMiddle east

Horizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2022 Financial Results

Fourth-Quarter 2022 Results: Net Sales of $942.0 Million GAAP Net Income of $120.4 Million; Adjusted EBITDA of $357.5 Million; Includes $37.3 Million of Acquired IPR&D and Milestones Expenses

United statesDennis riedlGeoff curtisTim walbertTina venturaRay gordonErin linnihanClinical program expected toAlkem laboratories incAmgen incCorporate affairsApotex incNet salesYear over increaseRecord adjustedOperating cash flow

Horizon Therapeutics plc Reports Third-Quarter 2022 Financial Results; Increases Full-Year 2022 Net Sales and Adjusted EBITDA Guidance; Increases TEPEZZA and KRYSTEXXA Peak Annual Net Sales Expectations

Third-Quarter 2022 Results: Net Sales of $925.4 Million GAAP Net Income of $135.8 Million; Adjusted EBITDA of $335.3 Million, Which Includes $19.0 Million of Acquired IPR&D and Milestones

United statesGeoff curtisTim walbertTina venturaRay gordonErin linnihanCompanies that careShare repurchase programSubcutaneous sc administration trialAmerican college of rheumatologyKey clinical development programsDevelopment for the treatment of autoimmune diseasesResearch in multiple sclerosisClinical programApotex incDivision of corporation

Alnylam Completes Enrollment in APOLLO-B Phase 3 Study of Patisiran in Transthyretin-Mediated (ATTR) Amyloidosis Patients with Cardiomyopathy

Alnylam Completes Enrollment in APOLLO-B Phase 3 Study of Patisiran in Transthyretin-Mediated (ATTR) Amyloidosis Patients with Cardiomyopathy
morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomChristine regan lindenboomJosh brodskyRena denoncourtAlnylam pharmaceuticals incExchange commissionAlnylam pharmaceuticalsEuropean unionAlnylam completes enrollmentAmyloidosis patientsFurthest progressed randomizedPlacebo controlled pivotal studyTopline results expectedVice presidentPrescribing information